[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-sclerosis-ms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-sclerosis-ms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,54,83,114,137,171,198,225,246,267,293,320,341,366,388,414,443,463,489,515,555,580,608,631],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100466892","phase-1-assessing-changes-in-multi-parametric-mri-in-ms-patients-taking-clemastine-fumarate-as-a-myelin-repair-therapy-100466892",false,"NCT05359653","Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","ReVIVE","Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any assessment being performed.\n* Patients diagnosed with relapsing remitting multiple sclerosis and a disease duration of \\\u003C 15 years\n* Male or female patients aged 18-55 years (inclusive)\n* Use of appropriate contraception during period of trial (women). Before entry women must be:\n\n  * Post-menopausal for at least 1 year OR\n  * Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, male partner vasectomy or otherwise incapable of pregnancy) OR\n  * Practicing a highly effective method of birth control if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study OR\n  * Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) OR\n  * Practicing true abstinence (when this is in line with the preferred and usual lifestyle of the subject) Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not an acceptable method.\n\nExclusion Criteria:\n\n* Radiologic identification of marked brain atrophy relative to patients age based on recent MRI and interpretation of expert neuroradiologist or PI\n* New lesion in most recent MRI (within 3 months)\n* Hypersensitivity to clemastine or other arylalkylamine antihistamines, or any of the excipients.\n* Treatment with corticosteroids within 30 days prior to screening.\n* Expanded Disability Status Scale (EDSS) ≥ 4.5\n* History of significant cardiac conduction block.\n* History of cancer.\n* Suicidal ideation or behavior in 6 months prior to baseline.\n* Pregnancy, breastfeeding or planning to become pregnant.\n* Involved with other study protocols simultaneously without prior approval.\n* Concomitant use of any other putative remyelinating therapy as determined by the investigator.\n* Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination.\n* Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide.\n* Serum creatinine \\> 1.5 mg\u002FdL; aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase \\> 2 times the upper limit of normal. (Reported within 72 hours)\n* History of drug or alcohol abuse within the past year.\n* Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid \\[MMA\\] and homocysteine) or untreated hypothyroidism.\n* Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases that in the PI's judgment may affect the interpretation of study results or patient safety.\n* History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study\n* Inability to participate in MRI, including extreme claustrophobia.\n* Any dental braces or permanent or undetachable metals in the jaw or face.","ALL","18 Years","55 Years",{"count":21,"type":22},74,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.\n\nNo reparative therapies exist for the treatment of multiple sclerosis. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at the University of California, San Francisco (UCSF). Following in vivo validation, an FDA IND exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577.\n\nThis study seeks to follow up on that study and examine clemastine fumarate's protective and reparative effects in the context of chronic demyelinating brain lesions as imaged by multi-parametric MRI assessments. The investigators will be assessing the effects of clemastine fumarate as a remyelinating therapy and assessing its effect on MRI metrics of chronic lesions found in patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis.\n\nIn addition to using conventional multi-parametric MRI assessments, this study will also evaluate a new MRI technique called Ultrashort Echo Time (UTE) MRI to assess the effects of clemastine fumarate as a remyelinating therapy of chronic lesions found in patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis and compare it to the other assessments.",[29,30,31,32,33,34,35],"Multiple Sclerosis (MS)","Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Chronic Progressive","Multiple Sclerosis Relapse","Multiple Sclerosis Brain Lesion","Multiple Sclerosis Benign",[37,38,39,40],"multiple sclerosis","mri","brain","spinal cord","RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-02","ACTUAL",{"date":47,"type":45},"2023-08-01",{"date":49,"type":22},"2027-06-01",{"name":51,"class":52},"University of California, San Francisco","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100644891","phase-1-a-study-of-c-car168-in-the-treatment-of-autoimmune-diseases-refractory-to-standard-therapy-100644891","NCT07676266","A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Anti-CD20\u002FB-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as Multiple sclerosis (MS)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FMyasthenia Gravis (MG)\u002FSystemic Lupus Erythematosus (SLE)\u002F Systemic Sclerosis (SSc)\u002F Immune-Mediated Necrotizing Myopathy (IMNM) according to recognized diagnostic criteria for at least 6 months.\n* Prior treatment failure with standard therapy.\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.\n* Any contraindication to lumbar puncture for MS or NMOSD.","70 Years",{"count":63,"type":22},18,[25],"This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy",[29,67,68,69,70,71],"Myasthenia Gravis (MG)","Neuromyelitis Optica Spectrum Disorder","Systemic Lupus Erythematosus","Systemic Sclerosis","Immune-Mediated Necrotizing Myopathy",[73],"CD20\u002FBCMA-directed CAR-T cells","NOT_YET_RECRUITING","2026-06-24",{"date":42,"type":45},{"date":78,"type":22},"2026-07",{"date":80,"type":22},"2028-10",{"name":82,"class":52},"The Affiliated Hospital of Qingdao University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100642993","telesm-edunursing-a-personalised-nursing-intervention-for-people-with-multiple-sclerosis-100642993","NCT07640698","TELESM-edu.Nursing: a Personalised Nursing Intervention for People With Multiple Sclerosis","TELESM-edu.Nursing: Efficacy of a Personalised Nursing Intervention for the Management of People With Multiple Sclerosis","TELESM-edu","Inclusion Criteria:\n\n* Patients of both sexes (male and female)\n* Age 18 years or older\n* Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), or secondary progressive multiple sclerosis (SPMS)\n* Currently receiving pharmacological treatment for multiple sclerosis\n* Expanded Disability Status Scale (EDSS) score of 7.5 or lower\n* Ability to read and understand Italian\n* Ability to provide written informed consent\n* Access to a suitable device (smartphone, tablet, or computer with a webcam)\n* Access to a home internet connection\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Expanded Disability Status Scale (EDSS) score higher than 7.5\n* Presence of psychiatric disorders that may interfere with participation in the study\n* Presence of cognitive impairment that may interfere with participation in the study",{"count":92,"type":22},110,[94],"NA","The primary aim of this study is to evaluate the impact of the telenursing intervention \"TELESM-edu.nursing\" on people with Multiple Sclerosis (pwMS), specifically focusing on their navigational capacity within the healthcare system (Navigation Health Literacy) and their perceived level of Health Literacy.\n\nThe study will also assess the effectiveness of the intervention in improving patient satisfaction with current therapy, patients' beliefs and attitudes towards the prescribed therapeutic regimen, satisfaction of informational needs, trust in nurses, and degree of disability.\n\nThe secondary objective is to evaluate the feasibility and sustainability of a personalised telenursing programme for pwMS. Feasibility will be assessed based on: (I) the ability to recruit and retain participants, measured through adherence rates and dropout rates in the intervention group; (II) participants' acceptability, usability, and satisfaction with the intervention; and (III) healthcare staff satisfaction and perceived usability of the intervention.\n\nThe main research questions addressed in this study are:\n\nDoes the \"TELESM-edu.nursing\" intervention improve patients' Navigation Health Literacy and overall Health Literacy levels? Does the intervention improve patient satisfaction with therapy and fulfilment of informational needs? Does the intervention positively influence patients' beliefs and attitudes towards their treatment? Does the intervention increase trust in nurses? What is the impact of the intervention on patients' level of disability? Is the telenursing programme feasible, acceptable, and sustainable for both patients and healthcare professionals?\n\nBoth study groups will receive the standard in-person informational and educational programme, as well as routine follow-up visits according to the established care pathway. Participants assigned to the intervention group will additionally receive a personalised educational programme lasting six months. This programme will be delivered monthly by a nurse through educational video pills and nurse-led teleconsultations.\n\nParticipants will be required to watch the video pills and take part in teleconsultations.",[29,97],"Telenursing",[97,99,100,101,102,103,104,105],"Navigation Health Literacy","Health Literacy","Needs Assessment","Nurses","Therapeutics","Multiple sclerosis","Disability Evaluation","2026-06-05",{"date":108,"type":45},"2026-06-11",{"date":78,"type":22},{"date":111,"type":22},"2027-06",{"name":113,"class":52},"G. d'Annunzio University",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":53},"100642966","my-ms-toolkit-an-internet-based-depression-self-management-program-for-adults-living-with-multiple-sclerosis-100642966","NCT07636434","My MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis","Inclusion Criteria:\n\n* Self-reported diagnosis of MS (with screening questions such as current disease modifying therapy)\n* At least 18 years of age\n* Can read, write, and speak in English\n* Score of \\>4 on the Patient Health Questionnaire, indicating at least mild depressive symptoms\n* Have access to an internet-connected device for accessing the intervention\n\nExclusion Criteria:\n\n* Previous diagnosis of bipolar disorder or schizophrenia\n* Started medication for depression or anxiety in the past 2 months\n* Currently undergoing psychotherapy for depression\n* Are of moderate or high risk for suicide on the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Participating in another clinical trial",{"count":92,"type":22},[94],"We are conducting this study to test if the new Toolkit depression module is accessible and helpful for people with multiple sclerosis (MS) in decreasing depression severity.",[124,29],"Multiple Sclerosis",[37,126,127],"depression","self-management","2026-06-02",{"date":130,"type":45},"2026-06-09",{"date":132,"type":22},"2026-09-01",{"date":134,"type":22},"2027-11",{"name":136,"class":52},"University of Washington",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":53},"100627085","mri-based-lesion-differentiation-in-older-patients-with-multiple-sclerosis-100627085","NCT07444047","MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis","Quantitative Susceptibility Mapping for Lesion Differentiation in Aging Multiple Sclerosis","Inclusion Criteria Multiple Sclerosis (MS) cohort (AgeMS):\n\n* Age 50-70 years\n* Clinically confirmed diagnosis of multiple sclerosis\n* Participation in the AgeMS study at Oslo University Hospital\n\nInclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort:\n\n* Age 50-80 years\n* Radiological evidence of hypertensive small vessel disease on MRI\n* Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis\n\nExclusion Criteria Multiple Sclerosis (MS) cohort:\n\n* MRI contraindications\n* Severe psychiatric comorbidity\n* Major functional disability unrelated to MS or CSVD\n\nExclusion Criteria Cerebral Small Vessel Disease (cSVD) control cohort:\n\n* MRI contraindications\n* Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0\n* Genetic or inflammatory vasculopathies\n* Persistent neurological deficits\n* Severe psychiatric comorbidity\n* Major functional disability unrelated to CSVD","50 Years","80 Years",{"count":147,"type":22},1000,"OBSERVATIONAL","This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging.\n\nParticipants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included.\n\nThe goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings in older patients with MS.",[29,151],"Cerebral Small Vessel Diseases",[153,154,155,156,157,158,159,160,161],"Quantitative Susceptibility Mapping","QSM","White Matter Lesions","MRI","Lesion Differentiation","Aging","Neuroimaging","Demyelination","Small vessel Disease","2026-05-28",{"date":164,"type":45},"2026-06-01",{"date":166,"type":45},"2026-05-11",{"date":168,"type":22},"2031-12-31",{"name":170,"class":52},"Oslo University Hospital",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100640507","essential-oils-for-urinary-symptoms-in-multiple-sclerosis-patients-100640507","NCT07599189","Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients","Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.","AROMA-MS","Inclusion Criteria:\n\n* Confirmed diagnosis of Multiple Sclerosis (any form)\n* Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening\n* Age between 18 and 65 years\n* Willing and able to provide written informed consent\n* Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period\n\nExclusion Criteria:\n\n* Active urinary tract infection confirmed by urine culture at screening\n* Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)\n* Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary\n* Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application\n* Pregnancy, breastfeeding, or planning to become pregnant during the study period\n* Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires\n* Current use of an indwelling urinary catheter or practice of intermittent self-catheterization",{"count":180,"type":22},60,[94],"The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.\n\nThe main questions it aims to answer are:\n\n* Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?\n* What medical problems do participants have when using essential oil aromatherapy?\n\nResearchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.\n\nParticipants will:\n\n* Use essential oil aromatherapy or a placebo oil every day for 6 weeks\n* Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day\n* Fill out quality of life questionnaires at the beginning and end of the study",[29,184,185,186,187],"Neurogenic Bladder Disorder","Urinary Incontinence (UI)","Urinary Urgency","Lower Urinary Tract Symptoms (LUTS)","2026-05-16",{"date":190,"type":45},"2026-05-20",{"date":192,"type":22},"2026-09",{"date":194,"type":22},"2027-03",{"name":196,"class":52},"University of Oran 1",2,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":53},"100633423","phase-1-safety-and-pharmacodynamics-of-qh103-cell-injection-in-the-treatment-of-patients-with-relapsedrefractory-antibody-mediated-neurological-autoimmune-diseases-100633423","NCT07526493","Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed\u002FRefractory Antibody-Mediated Neurological Autoimmune Diseases.","An Open-Label Clinical Study to Evaluate the Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed\u002FRefractory Antibody-Mediated Neurological Autoimmune Diseases.","Common Inclusion Criteria:\n\n1. Aged 18-75 years (inclusive), any gender.\n2. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or practice abstinence during the study treatment period and for at least 6 months after the end of the study treatment. Female subjects of childbearing potential must have a negative serum HCG test within 7 days before study enrollment and must not be breastfeeding.\n3. The subject's expected survival, as judged by the investigator, is ≥12 weeks.\n4. Voluntarily participate in this trial and sign the informed consent form.\n\nDisease-Specific Inclusion Criteria:\n\n1、Multiple Sclerosis (MS): Clinically confirmed as progressive MS (including Primary Progressive PPMS or Secondary Progressive SPMS) or Relapsing-Remitting MS (RMS) according to the revised 2017 McDonald criteria. Disability status at screening must meet an EDSS score of 2-7 (inclusive) .For participants with RMS, despite standardized use of DMTs, they must have documented evidence meeting one of the following conditions prior to signing the informed consent:\n\n1. Two relapses were recorded within the first 2 years of screening;\n2. One recurrence was recorded within the first year prior to screening;\n3. Select the results of Gd-enhanced MRI scans that were positive within the previous year (if there is no record of a positive Gd-enhanced scan in the previous year, the results of the screening MRI scan can be used).\n\n2、Neuromyelitis Optica Spectrum Disorder (NMOSD): Participants with AQP4 antibody-positive NMOSD meeting the 2015 IPND NMOSD diagnostic criteria, and meeting one of the following:\n\n1. Treatment with at least one immunosuppressant for over 1 year, or intolerance to immunosuppressant treatment, with suboptimal symptom control.\n2. At least 2 documented relapses within the last 12 months, or 3 documented relapses within the last 24 months with at least 1 relapse occurring within the 12 months prior to screening.\n\n3、Autoimmune Encephalitis (AE): Participants with a clinical diagnosis of Autoimmune Encephalitis based on the 2016 International Diagnostic Criteria, meeting all of the following requirements:\n\n1. Positive for at least one relevant autoantibody;\n2. Inadequate symptom control with or intolerance to previous standardized treatment with glucocorticoids and at least one immunosuppressant\u002Fimmunomodulator (including CD20 monoclonal antibody);\n3. An episode of autoimmune encephalitis within 3 months prior to signing the informed consent form;\n4. Disability status at screening meeting a modified Rankin Scale (mRS) score ≥ 2 or a CASE score ≥ 4 .\n\n4、Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Participants diagnosed with antibody-positive CIDP according to the 2021 EAN\u002FPNS diagnostic criteria, with an INCAT Disability Scale total score between 2 and 9, and meeting one of the following:\n\n1. Inadequate symptom control despite standardized use of at least one first-line therapy (corticosteroids, intravenous immunoglobulin, or plasma exchange) for over 3 months;\n2. Intolerance to corticosteroids, intravenous immunoglobulin, and plasma exchange due to side effects or other reasons.\n\n5、Myasthenia Gravis (MG): Participants diagnosed with antibody-positive MGFA Class II-IV Myasthenia Gravis according to the 2020 MGFA diagnostic criteria, with a Myasthenia Gravis Activities of Daily Living (MG-ADL) profile (Appendix 6) total score ≥ 6, and meeting one of the following:\n\n1. Standardized treatment with at least one immunosuppressant for over 1 year, with one of the following indicating inadequate control: (1) persistent weakness affecting daily life, (2) worsening MG symptoms and\u002For crisis episodes despite standard treatment, or (3) intolerance to immunosuppressant therapy;\n2. Requiring maintenance therapy with plasma exchange or intravenous immunoglobulin.\n\n6、Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody----- - Associated Disease (MOGAD): Participants with a clinical diagnosis of MOGAD based on the 2023 International MOGAD Diagnostic Criteria, meeting all of the following:\n\n1. Positive for MOG autoantibody via cell-based assay (CBA);\n2. Disability status at screening meeting a modified Rankin Scale (mRS) score ≥ 2.\n3. Inadequate symptom control with or intolerance to previous standardized treatment with glucocorticoids and at least one immunosuppressant \u002F immunomodulator (including CD20 monoclonal antibody).\n\n7、Idiopathic Inflammatory Myopathies (IIM): Patients clinically diagnosed with refractory, antibody-positive Idiopathic Inflammatory Myopathy (IIM) based on the 2017 European Alliance of Associations for Rheumatology\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria. At screening, at least one muscle enzyme (CK, AST, ALT, ALD, LDH) must be ≥1.5 times the upper limit of normal (ULN); OR the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) for dermatomyositis must be ≥6 (Appendix 7); OR there must be evidence of active myositis within the last 6 months from at least one of the following: MRI, electromyography, or muscle biopsy. The patient must test positive for at least one myositis-specific antibody (MSA), myositis-associated antibody (MAA), or antinuclear antibody (ANA). Additionally, they must meet one of the following criteria:\n\n1. Treatment with corticosteroids for at least 1 month, combined with standardized use of at least one immunosuppressant\u002Fimmunomodulator (e.g., azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, cyclophosphamide, leflunomide, intravenous immunoglobulin, etc.) for over 3 months, resulting in inadequate symptom control.\n2. Intolerance to the aforementioned conventional treatment regimens due to side effects or other reasons.\n\nExclusion Criteria:\n\n1. History of severe drug allergy or allergic diathesis.\n2. Presence of or suspected uncontrolled or treatment-requiring fungal, bacterial, viral, or other infections.\n3. Organ function that does not meet the following requirements (except for abnormalities caused by the autoimmune disease itself):\n\n   1. Bone Marrow Function: White blood cell count ≥1×10⁹\u002FL; absolute neutrophil count ≥1×10⁹\u002FL (no treatment with colony-stimulating factors within 2 weeks prior to the test); hemoglobin ≥60 g\u002FL.\n   2. Liver Function: ALT ≤3×ULN (except if elevated due to inflammatory myopathy); AST ≤3×ULN (except if elevated due to inflammatory myopathy); Indirect bilirubin (IBIL) ≤1.5×ULN (except for Gilbert's syndrome); Total bilirubin ≤3.0×ULN.\n   3. Renal Function: Creatinine clearance (CrCl) ≥30 mL\u002Fmin (eGFR ≥30 mL\u002Fmin\u002F1.73m²) (calculated by Cockcroft-Gault formula, except for acute decreases in CrCl due to the disease itself).\n   4. Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN.\n   5. Cardiac Function: Left ventricular ejection fraction (LVEF) ≥55% and no clinically significant cardiac disease.\n4. Subjects with a history indicative of congenital immunoglobulin deficiency.\n5. History of active\u002Funresolved malignant tumors within the past 5 years.\n6. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer above the detection limit; positive for hepatitis C virus (HCV) antibody with detectable peripheral blood HCV RNA; positive for human immunodeficiency virus (HIV) antibody; or positive for Treponema pallidumserology.\n7. History of definite psychiatric disorders or history of substance abuse involving psychotropic drugs that cannot be discontinued.\n8. Participation in any other clinical trial within 3 months prior to enrollment.\n9. Prior treatment with CAR-T cell therapy.\n10. History of severe adverse reactions to cyclophosphamide or fludarabine.\n11. History of other autoimmune diseases (e.g.,Crohn's disease, systemic lupus erythematosus) that, within the past 2 years, have resulted in end-organ damage or required systemic immunosuppressive therapy (excluding the disease populations specified for enrollment in the study protocol).\n12. Myasthenia gravis crisis not effectively controlled within 2 weeks prior to enrollment.\n13. History of cerebrovascular accident, including transient ischemic attack or stroke, within 6 months prior to enrollment.\n14. Male or female participants unwilling to practice contraception from the time of informed consent until 6 months after treatment completion.\n15. Any medical condition that may interfere with the assessment of the safety or efficacy of the study treatment.\n16. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulation therapy.\n17. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.","75 Years",{"count":207,"type":22},6,[25],"This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to \"3+3\" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent\u002Frefractory antibody-mediated neurological autoimmune diseases.",[29,211,212,213,67,214,215],"Neuromyelitis Optica Spectrum Disorder (NMOSD)","Autoimmune Encephalitis (AE)","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Disease (MOGAD)","Idiopathic Inflammatory Myopathies (IIM)","2026-05-07",{"date":218,"type":45},"2026-05-12",{"date":220,"type":45},"2026-04-01",{"date":222,"type":22},"2028-12-31",{"name":224,"class":52},"Tongji Hospital",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":197},"100582255","a-palliative-care-model-impact-on-knowledge-and-attitudes-100582255","NCT06860932","A Palliative Care Model Impact on Knowledge and Attitudes","Inclusion Criteria:\n\n* Diagnosed with MS, NMOSD, or anti-MOG, at least 2 years after their diagnosis.\n* Aged 18-65\n* Speak English since all instruments are available in English.\n\nExclusion Criteria:\n\n* Visually impaired (note, hearing impaired is not an exclusion criterion as the video is closed captioned).\n* Psychological state not appropriate for PC discussions as determined by the Patient Health Questionnaire 9 (PHQ9).\n* A score of 11 or higher, indicative of major depressive disorder, will be referred to immediate management and excluded from the study.\n* Unable to participate in PC discussions due to cognitive impairment as determined by the Processing Speed Test (PST) score below -1.5 Z score.","65 Years",{"count":233,"type":22},50,[94],"This study is using a central, computer-generated simple randomization technique. Participants will be randomly assigned to groups within the constraints of ensuring balanced representation of gender, ethnicity, and race.\n\nOne-half of the patients are randomized to the decision aid video model, and one-half will serve as controls and receive a palliative care (PC) informational sheet. Sessions are designed to be consistent with PC principles of care using constructs from the Murray's transition theory including knowledge development coupled with advanced care planning (ACP)-to drive palliative care alongside curative treatment, and to support people with chronic progressive illnesses. The 2 groups will complete the demographic forms, and pre- and post-tests, at baseline and after three months. The intervention group will view the video decision aid, which takes 10 minutes, during their follow up appointment. The controls will read written information of the same content shown on the video and will complete similar questionnaires. The video opens with empathic statements regarding the situation in which patients may find themselves, including an introduction about medical decisions, and statements regarding values and spiritual beliefs and their impact on decision-making. The video translates the information into actionable medical orders using a three-goal framework: life-prolonging care, limited\u002Fblended care, and comfort care. The video describes the features of each of the goals of care and the risks and benefits of each option using visual images that illustrate the interventions. Patients will review the video using iPads and will be able to review the video again as needed. The Flesch-Kincaid ease score for the video narration is 71.6; for the \"Conversation\" piece, it is 65.9. These indicate that the passages require approximately a 7th or 8th grade reading level, which Flesch suggests makes them \"easy to read\" and \"plain English,\" respectively.\n\nThe goal of the video intervention is to help patients express their values and health goals, while achieving their life and core values. The intervention group will view the video which includes modules to teach patients strategies for expressing their concerns and enhance their self-efficacy, helping them overcome any barriers. To enhance intervention fidelity, an ACP facilitator guide will be developed as reference for the intervention implementation. It will detail the key topics and purposes of each session of the intervention, the guiding questions, and the facilitation skills.\n\nAim 1: To explore the preferences of patients with neuroinflammatory diseases, PC knowledge, decisional conflict, and preparation for decision making among 50 adult (18-65 years old) patients randomly assigned to one of two PC modalities: 1. a video depicting PC goals of care (intervention group, n=25), or 2. standard usual care using PC written information (control group, n=25).\n\nH1a: Patients randomized to the video will have higher documented preferences and fewer preferences for life-prolonging interventions (primary outcome) than the control group. The intervention group will have greater knowledge, lower decisional conflict, and greater preparation for decision making than those randomized to the control group.\n\nAim 2: To compare PC conversations and documentation at 3 months among patients with neuroinflammatory diseases.\n\nH2: Patients randomized to the video will have more PC conversations and higher rates of PC documentation after 3 months.",[237],"Multiple Sclerosis, MS","2026-04-20",{"date":240,"type":45},"2026-04-22",{"date":242,"type":45},"2025-02-01",{"date":42,"type":22},{"name":245,"class":52},"Hunter College of City University of New York",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":53},"100633162","phase-1-a-study-on-the-safety-and-tolerability-of-universal-star-t-cell-therapy-for-multiple-sclerosis-100633162","NCT07523100","A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.","A Clinical Study on the Safety and Tolerability of Universal STAR-T Cell Injection in Patients With Multiple Sclerosis.","Inclusion Criteria:\n\n* 1\\. Aged from 18 to 65 years (inclusive), with no gender restriction.\n* 2\\. Patients with MS who have been diagnosed according to the specified diagnostic criteria in the past and currently have no effective treatment options need to meet the following requirements, including:\n\n  1. According to the revised 2024 McDonald diagnostic criteria, they are clinically diagnosed with progressive MS (including primary progressive PPMS or secondary progressive SPMS) or relapsing-remitting MS (RRMS), and their disability status at the time of screening meets an EDSS score of 2-7 (inclusive).\n  2. For RRMS patients, they need to meet any of the following conditions: a) They have failed treatment with ≥1 effective DMT (fenogomide, cinemodide, ozamod, and anti-CD20 monoclonal antibody therapy, etc.); b) They have had at least 2 clinical relapses in the past 2 years, or they have had 1 clinical relapse in the past 2 years and MRI shows ≥1 new Gd-enhanced lesion, or they have had ≥1 new Gd-enhanced lesion on MRI within the past 6 months; c) There are ≥2 active Gd-enhanced lesions on T1-weighted brain MRI at the time of screening.\n* 3\\. The functions of important organs should meet the following requirements:\n\n  1. Bone marrow function should satisfy: a. Neutrophil count ≥ 1×109\u002FL (no colony-stimulating factor treatment within 2 weeks before the examination, and neutrophil reduction caused by the disease is excluded); b. Hemoglobin ≥ 60g\u002FL;\n  2. Liver function: ALT ≤ 3×ULN (ALT elevation caused by the disease can be excluded); AST ≤ 3×ULN (AST elevation caused by the disease can be excluded); TBIL ≤ 1.5×ULN (TBIL elevation caused by the disease can be excluded);\n  3. Kidney function: Creatinine clearance rate (CrCl) ≥ 30 ml\u002Fminute (Cockcroft\u002FGault formula, acute CrCl decline caused by the disease is excluded);\n  4. Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN;\n  5. Cardiac function: Good hemodynamic stability;\n* 4\\. For female subjects with reproductive capacity and their male partners, as well as male subjects whose female partners are of childbearing age, they are required to adopt medically approved contraceptive measures or abstain from sexual activity during the study treatment period and for at least 12 months after the end of the study treatment; female subjects of childbearing age must have a negative serum HCG test result within 7 days before study enrollment and must not be in the lactation period.\n* 5\\. Voluntarily participated in this clinical study, signed the informed consent form, had good compliance, and cooperated with the follow-up.\n\nExclusion Criteria:\n\nIf the subjects meet any of the following exclusion criteria, they will not be included in this study:\n\n* 1\\. The period of using immunosuppressants with therapeutic effects on the disease before enrollment is within five half-lives or the biological agents have been used for 4 weeks. For subjects who have received rituximab treatment, the time since the last use of rituximab is less than 3 months (except for those with B-cell reconstitution);\n* 2\\. Have a severe history of drug allergy or are allergic constitution;\n* 3\\. Have uncontrollable or require treatment infections such as fungi, bacteria, viruses, etc.;\n* 4\\. Have active tuberculosis at the time of screening;\n* 5\\. Have heart dysfunction (NYHA cardiac function classification \\> grade II) and cannot tolerate the study's lymphocyte purification and cell reinfusion.\n* 6.Subjects with congenital immunoglobulin deficiencies;\n* 7\\. Subjects with a history of unremitting malignant tumors within the past five years;\n* 8\\. Subjects with end-stage renal failure;\n* 9\\. Subjects with positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and peripheral blood HBV DNA titer higher than the detection limit; subjects with positive hepatitis C virus (HCV) antibody and positive HCV RNA in peripheral blood; subjects with positive human immunodeficiency virus (HIV) antibody; subjects with positive syphilis test results;\n* 10\\. Male and female subjects who are pregnant or have a fertility plan during the participation in this study or within 2 years after receiving study treatment;\n* 11\\. Subjects that the researchers consider have other reasons that prevent them from being included in this study.",{"count":5,"type":22},[25],"This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study.\n\nThe main objective is to explore the safety and tolerability of the universal STAR-T cell injection in patients with progressive or relapsing-remitting multiple sclerosis (MS).The secondary objectives are to evaluate the efficacy of the universal STAR-T cell injection in treating patients with progressive or relapsing-remitting MS; and to assess the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the universal STAR-T cell injection.\n\nThe primary endpoint of this study is the incidence rate of dose-limiting toxicity (DLT), as well as the types, severity and frequency of adverse events (AE).The secondary research endpoints of this study are the efficacy endpoints as well as the expansion and persistence of the universal STAR-T cells in the body.\n\nThis study is an exploratory clinical trial of the universal STAR-T cell injection for the treatment of progressive or relapsed-remitting MS. The study will be conducted in two phases: dose escalation and dose expansion. The dose escalation group 1 (1.5E6 STAR-T cells) begins, followed by dose escalation group 2 (3E6 STAR-T cells), and dose escalation group 3 (4.5E6 STAR-T cells).\n\nExpansion study phase: After the dose escalation stage is completed, based on the safety, PK results and preliminary efficacy data of each dose group during the escalation stage, the recommended dose will be determined for the dose expansion study. It is planned to include 3 to 6 subjects to further systematically evaluate the safety and efficacy of the universal STAR-T cell.\n\nThis study includes the screening period (from D-28 to D-6), the pre-clearance treatment and rest observation period (from D-5 to D-1), the cell infusion and main study endpoint observation period (from D0 to W12 after infusion), and the follow-up period (from W12 after infusion to W104).",[29],[124],"2026-04-04",{"date":260,"type":45},"2026-04-13",{"date":262,"type":22},"2026-04-07",{"date":264,"type":22},"2029-04-01",{"name":266,"class":52},"Daishi Tian",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100629396","serious-game-rehabilitation-and-brain-plasticity-in-ms-100629396","NCT07474129","Serious Game Rehabilitation and Brain Plasticity in MS","Brain Reorganization After Serious Game -Based Cognitive Rehabilitation in Multiple Sclerosis","REVEILLE","Inclusion Criteria:\n\n* People with relapsing-remitting or progressive MS defined according to the 2010 revised McDonald criteria \\[56\\]\n* Cognitive complaints and deficits in at least one score on the initial neuropsychological examination (\\\u003C5th percentile of the reference group)\n* Aged between ≥ 18 and ≤ 65 years\n* No defined relapse for at least 6 weeks\n* At least 4 weeks since a corticosteroid bolus\n* Patient with an internet connection\n* Patient covered by social security\n* Signed informed consent\n\nExclusion Criteria:\n\n* Claustrophobia preventing MRI;\n* Contraindication to MRI;\n* Wearing fixed dental braces;\n* Unable to receive oral and written information;\n* Unable to use the software (due in particular to motor and\u002For sensory difficulties);\n* Neurological or psychiatric comorbidity, other than MS and anxiety-depression syndrome,\n* Patient with severe anxiety-depression syndrome (BDI-FS \\> 10),\n* Pregnant or breastfeeding women\n* Taking neuroleptic treatment\n* Person under guardianship or curatorship\n* Person deprived of liberty",{"count":276,"type":22},40,[94],"This prospective, interventional, longitudinal, multicentre study aims to evaluate the impact of the \"Serious game\", an innovative cognitive remediation tool on brain reorganization in Multiple sclerosis patients, using functional Magnetic resonance imaging (MRI). The serious game is a tool combining the motivational mechanisms of video games with cognitive remediation techniques.",[29],[104,281,282,283],"Serious Game","Cognitive rehabilitation","Magnetic resonance imaging","2026-03-11",{"date":286,"type":45},"2026-03-16",{"date":288,"type":22},"2026-06",{"date":290,"type":22},"2030-03",{"name":292,"class":52},"Lille Catholic University",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":53},"100425422","spinal-cord-lesion-detection-in-multiple-sclerosis-using-novel-mri-sequences-100425422","NCT04819737","Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences","Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study","Inclusion Criteria:\n\n* Diagnosis of multiple sclerosis according to established international criteria\n* Steroid free period: \\> 4 weeks\n* Participation in the Swiss MS Cohort (SMSC) study\n\nExclusion Criteria:\n\n* . History of severe (other) neurological, internal or psychiatric disease with SC affection\n* MRI-related exclusion criteria (questionnaire):\n\n  1. Paramagnetic and\u002For superparamagnetic foreign objects in the body (especially when located close to the SC)\n  2. Pacemaker\n  3. Claustrophobia\n  4. Pregnancy, lactation\n  5. Known hypersensitivity to gadolinium-based contrast media",{"count":301,"type":22},10,[94],"This study is to evaluate the sensitivity and intra-\u002Finter-observer agreement of the averaged magnetization inversion recovery acquisitions (AMIRA) in spinal cord (SC) Multiple sclerosis (MS) lesion detection and to evaluate the additional clinical value of this sequence in clinical settings.",[29],[306,307,308,309,310],"spinal cord (SC) pathology","demyelinating lesions","Spinal cord MRI","Averaged magnetization inversion recovery acquisitions (AMIRA) sequence","Swiss MS Cohort (SMSC)","2026-03-03",{"date":313,"type":45},"2026-03-05",{"date":315,"type":45},"2022-07-18",{"date":317,"type":22},"2027-12",{"name":319,"class":52},"University Hospital, Basel, Switzerland",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":332,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":53},"100577580","effect-of-music-therapy-on-pain-in-people-with-multiple-sclerosis-100577580","NCT06800144","Effect of Music Therapy on Pain in People With Multiple Sclerosis","Effect of Telerehabilitation-Based Heart Rate-Synchronized Motor Imagery Music Therapy on Pain, Autonomic Function and Psychosocial Parameters in People With Multiple Sclerosis","Inclusion Criteria:\n\n* Being between the ages of 18-65.\n* Having a definite MS diagnosis according to the 2017 McDonald criteria.\n* Having a pain level of at least 3 and above on the numerical pain scale for at least 3 months.\n* Not having had an attack in the last 3 months.\n* Having a tablet or computer with an active internet connection that is suitable for videoconferencing.\n* Having a smartphone to which the heart rate monitor can be connected with the Bluetooth feature so that the heart rate synchronized music therapy training can be given.\n* Having sufficient smartphone\u002Ftablet or computer knowledge to participate in the study or having a relative who can help in this regard.\n* No change in the medications used for pain in the last 2 months.\n* Not receiving any additional treatment other than routine treatments.\n* Being able to read and understand Turkish.\n\nExclusion Criteria:\n\n* Having a serious musculoskeletal, cardiovascular, pulmonary, metabolic or other disease that would prevent participation in the study.\n* Having a condition other than MS that can cause pain, such as cancer, diabetes, significant osteoarthritis or rheumatoid arthritis, based on laboratory or imaging findings\n* Having a psychiatric disease (such as active psychotic disorders, severe depression, anxiety disorders) that would prevent participation in the study and having a serious cognitive disorder determined by a physician that would prevent testing\n* Having a serious vision or hearing problem.\n* Being pregnant.",{"count":328,"type":22},45,[94],"Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and progressive neurological disease of the central nervous system, often seen between the ages of 20-30. Pain is a very common symptom in people with MS, with a prevalence of 63%. Pain in MS is a symptom that negatively affects individuals' fatigue, anxiety and depression levels, quality of life and sleep quality. In addition, chronic pain affects individuals' autonomic and cognitive functions. Music therapy is defined as the systematic use of music in a therapeutic relationship that aims to improve, maintain and develop emotional, physical and mental health. Music therapy protocols synchronized with heart rate can be effective on chronic pain through the regulation of the autonomic nervous system and activation of the parasympathetic nervous system. Studies indicate that music therapy, regardless of the population applied, is effective in the management of symptoms such as pain, depression and anxiety. Motor imagery training is a method that regulates cerebral cortex activity by exposing the brain to visual information and imagination, reduces abnormal cortical activation, and thus restores the brain's ability to change. Research indicates that the most effective motor imagery training in reducing pain is motor imagery training presented in a protocol graded from simple to complex motor tasks.\n\nThe grading principle applied in motor imagery training in the form of imagining movements from simple to complex and music therapy training presented in a rhythm matched with heart rate rhythm are effective approaches on chronic pain. It is thought that the treatment protocol in which these two methods are combined and their therapeutic effects are combined in MS rehabilitation may be more effective on pain and related factors in MS. The aim of the study is to show the effects of telerehabilitation-based heart rate-synchronized music therapy protocols on pain, heart rate, fatigue, anxiety, depression, quality of life, sleep quality, and information processing speed compared to MS individuals who continue their routine treatments.\n\n45 MS people with chronic pain will be included in the planned randomized controlled trial. The included participants will be randomized into 3 groups with 15 participants in each group. The evaluations will be performed three times before treatment, at 8th (post-treatment evaluation) and 12th weeks (follow-up evaluation). The participants' general pain intensity in the last 2 and 7 days, the presence of neuropathic pain, fatigue level, anxiety and depression levels, sleep quality, health-related quality of life and information processing speed will be evaluated. In addition, heart rate variability will be evaluated in order to evaluate the participants' autonomic functions. Telerehabilitation-based music therapy application will be given to the participants 2 days a week for 8 weeks using a videoconferencing platform under the guidance of a physiotherapist. The heart rates of the participants will be monitored throughout the session. The participants included in the first group will visualize the movements presented with the metronome sound in a rhythm matched to their heart rates, while the participants included in the second group will listen to relaxing\u002Frelaxing music without lyrics in a rhythm matched to their heart rates. When synchronization is achieved between the music rhythm and the heart rate in both groups, the music rhythm will be reduced. Participants included in the 3rd group will continue their routine treatment and will be evaluated only three times: at the beginning, after the 8th week and after the 12th week. The results obtained from this study will examine the effects of heart rate synchronized music therapy protocols on pain, autonomic function and psychosocial parameters in individuals with chronic pain and MS.",[237],[333],"Music Therapy in Multiple Sclerosis","2026-03-01",{"date":311,"type":45},{"date":334,"type":45},{"date":338,"type":22},"2027-12-01",{"name":340,"class":52},"Istanbul Bilgi University",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100619223","phase-1-a-study-of-c-car168-in-the-treatment-of-central-nervous-system-autoimmune-diseases-refractory-to-standard-therapy-100619223","NCT07341828","A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","An Exploratory Clinical Study of Anti-CD20\u002FB-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as Multiple Sclerosis (MS)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FAutoimmune Encephalitis(AiE)\u002FStiff Person Spectrum Disorder(SPSD) according to recognized diagnostic criteria for at least 6 months.\n* Prior treatment failure with standard therapy.\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.\n* Any contraindication to lumbar puncture.",{"count":349,"type":22},15,[25],"This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy",[29,353,354,355],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","Autoimmune Encephalitis","Stiff Person Syndrome",[73],"2026-01-13",{"date":359,"type":45},"2026-01-15",{"date":361,"type":22},"2026-02",{"date":363,"type":22},"2029-02",{"name":365,"class":52},"Huashan Hospital",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":53},"100617041","escalation-vs-induction-therapy-strategy-in-patients-with-early-onset-ms-after-age-50-100617041","NCT07313462","Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50","50-CENT","Inclusion Criteria:\n\n* Patients with RRMS onset after age 50\n* Patients who started their first disease-modifying therapy within 2 years of the first symptoms\n* Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)\n* Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)\n\nExclusion Criteria:\n\n\\- Patients with early progressive MS",{"count":374,"type":22},830,"The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.",[29],[29,378,379],"Escalation Therapy","Induction Therapy","2025-12-17",{"date":382,"type":45},"2026-01-02",{"date":384,"type":45},"2025-02-07",{"date":361,"type":22},{"name":387,"class":52},"University Hospital, Strasbourg, France",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":53},"100487958","multimodal-imaging-signatures-of-the-biological-mechanisms-underlying-neurodegeneration-in-multiple-sclerosis-100487958","NCT05633875","Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis","Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis: Long Term Predictive Value (IMAGIN-DEAL in MS)","IMAGINDEALinMS","Inclusion Criteria:\n\n* Multiple Sclerosis Patient already enrolled in one of those 3 protocols since 8 years or more: INFLASEP, FLUMATEP 1-2 or SHADOWTEP\n* Adult patient\n* Affiliation to a social security scheme or beneficiary of such a scheme (Except \"Aide Médicale d'Etat\")\n* Consent obtained\n\nExclusion Criteria:\n\n* Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace maker or the presence of an intra-ocular foreign body (a contra- indication questionnaire will be filled in beforehand)\n* Pregnancy, breast-feeding, lack of efficient contraception\n* Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases\n* Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)\n* Enrolment in another interventional study protocol for the duration of his or her participation without physician's agreement\n* Patient under legal protection",{"count":397,"type":22},80,"Multiple sclerosis (MS) is a chronic disease of the central nervous system characterised by multi-focal inflammatory and demyelinating lesions disseminated in the brain and in the spinal cord. Impressive advancements in the treatment of the autoimmune component of the disease have been achieved during the last decades, leading to a drastic reduction of white matter lesion accumulation and relapse rate along the disease course. However, the development of treatments effective for preventing or delaying the neurodegenerative component of the disease, that underly disability accrual and progression of the disease, remains a major challenge. The development of novel therapeutic strategies for neuroprotection that target all patients with MS is a priority objective for research in the next years. The critical steps towards identifying treatments that prevent neuro-axonal damage include a deep understanding of the mechanisms underlying neurodegeneration and the development of reliable biomarkers for assessing the efficacy of emerging drugs and for accelerating their translation to clinical use.\n\nThe team of Prof. Stankoff has pioneered an innovative imaging approach combining positron emission tomography and MRI, and succeeded in generating individual maps or key biological processes such as endogenous remyelination, neuroinflammation, or early damage preceding lesion formation. Using these approaches, it has been shown that these mechanisms were influencing disability worsening over the disease course, but the investigators still lack long term longitudinal studies for the validation of these advanced imaging metrics as prognosis markers. Recently, preliminary results have also suggested that a multimodal combination of advanced MRI sequences may have the potential to reproduce some PET results.\n\nIn this project the investigators propose to unravel the predictive value of individual maps of tremyelination, neuroinflammation, and early tissue damage, on long term disability worsening and to develop a novel imaging approach that aims to capture remyelination of lesions, ongoing inflammation invisible on T1 and T2 MRI sequences (subacute\u002Fchronic active lesions) and to predict short-term future disease activity (identify prelesional areas), from a single multimodal MRI acquisition in patients with MS.",[29],[401,156,402,403,404],"Multiple sclerosis (MS)","RRMS","long term predictive value","PET-MRI","2025-12-02",{"date":407,"type":45},"2025-12-09",{"date":409,"type":45},"2023-04-25",{"date":411,"type":22},"2026-06-25",{"name":413,"class":52},"Assistance Publique - Hôpitaux de Paris",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":17,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":53},"100371829","phase-1-a-phase-i-double-blind-study-of-metformin-acting-on-endogenous-neural-progenitor-cells-in-children-and-young-adults-with-multiple-sclerosis-100371829","NCT04121468","A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis","Inclusion Criteria:\n\n* Patients with a history of MS with anterior visual pathway involvement and longer than 6 months after presentation with ON or an acute demyelinating event\u002Frelapse\n* Age 10 year to 25 years and 11 months\n* Latency delay \\> 115 milliseconds on baseline full-field transient pattern reversal VEP in at least one eye (electrophysiological evidence of demyelination) or \\> 10 milliseconds difference between eyes, or Retinal Nerve Fiber Layer (RNFL) thickness on OCT of \\\u003C 90 µm in at least one eye or an inter-eye difference in the RNFL of 10 µm or more\n* Retinal Nerve Fiber Layer (RNFL) Thickness on baseline OCT ≥60 µm\n* If on an MS disease-modifying therapy, no changes in the therapeutic agent or dosing in the 6 months prior to study initiation\n* No significant renal or liver abnormalities\n* Expanded Disability Status Scale (EDSS) 0-6.0 (inclusive)\n* Has either English as his or her native language or English comprehension needed to complete the neuropsychological testing\n* Meet criteria for adequate organ function requirements as described below:\n\nAdequate renal function defined as:\n\nCreatinine clearance or radioisotope glomerular filtration rate (GFR) \\> 70 mL\u002Fmin\u002F1.73 m2 or serum creatinine based on age\u002Fgender as follows:\n\nRange Serum Creatinine Level (µmol\u002FL): Age 5 to \\\u003C12 years (male)=25-50, Age 5 to \\\u003C12 years (female)=25-50; Age 12 to \\\u003C15 years (male)=37-67, Age 12 to \\\u003C15 years (female)=37-67; Age 15 to \\\u003C19 years (male)=51-89, Age 15 to \\\u003C19 years (female)=40-69; Age ≥19 years (male)=58-110; Age ≥19 years (female)=46-92\n\nAdequate liver function defined as:\n\nTotal bilirubin \\\u003C 1.5 x upper limit of normal (ULN) for age SGOT (AST) or SGPT (ALT) \\\u003C 1.5 x upper limit of normal (ULN) for age\n\nExclusion Criteria:\n\n* A history of retinal pathology (major ophthalmologic disease \u002F concomitant ophthalmologic disorders)\n* Unstable and\u002For insulin-dependent (Type 1) diabetes, metabolic acidosis and\u002For lactic acidosis\n* History of unexplained hypoglycemia (\\\u003C2.8 mmol\u002FL)\n* Already on metformin\n* Concomitant use of any other putative remyelinating therapy as determined by the Principal\u002FQualified Investigator\n* Treatment for an acute attack with corticosteroids within 30 days prior to screening \u002F relapse within 30 days prior to screening\n* Concomitant use of insulin\n* Concomitant use of any drugs that are listed to have drug-drug interactions with metformin (i.e. calcium channel blockers, diuretics, etc.) as determined by Principal\u002FQualified Investigator\n* Lactate levels \\> 1.5x upper limit of normal\n* Pregnancy","10 Years","25 Years",{"count":423,"type":22},20,[25,26],"A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.",[29],[428,429,430,431,432,433],"remyelination","youth","white matter","neural precursor cells","clinical trial","metformin","2025-09-17",{"date":436,"type":45},"2025-09-23",{"date":438,"type":45},"2020-02-24",{"date":440,"type":22},"2027-10",{"name":442,"class":52},"The Hospital for Sick Children",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":450,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":197},"100589648","vista-protein-expression-of-monocyte-and-t-cell-subsets-in-multiple-sclerosis-and-its-clinical-correlation-100589648","NCT06957145","Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation","Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation: A 1-Year Follow-up Study","Inclusion Criteria:\n\n* Patients aged 18 years or older diagnosed with MS or CIS according to the 2017 McDonald criteria.\n* No diagnosis of any autoimmune disease or malignancy.\n* No new diagnosis of autoimmune disease or malignancy during the 1-year follow-up period.\n* No use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.\n* No vaccination within one month prior to blood sampling.\n* Not in the menstrual cycle at the time of blood sampling.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Presence of a previous or newly diagnosed autoimmune disease or malignancy at the time of blood sampling.\n* Use of antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), or steroid treatments within one month prior to blood sampling.\n* Vaccination within one month prior to blood sampling\n* Being in the menstrual cycle at the time of blood sampling\n* Patients without a definitive MS diagnosis according to the 2017 McDonald criteria will not be included in the study.",true,{"count":180,"type":22},"The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies.\n\nSpecifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated.\n\nFinally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.",[237],"2025-08-30",{"date":456,"type":45},"2025-09-03",{"date":458,"type":45},"2025-06-30",{"date":460,"type":22},"2026-12-30",{"name":462,"class":52},"Koç University",{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":58,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":479,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":53},"100535254","phase-1-a-study-of-c-car168-in-the-treatment-of-autoimmune-diseases-refractory-to-standard-therapy-100535254","NCT06249438","An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)\u002FAnti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy","CAR-AID","Inclusion Criteria:\n\n* 18 to 70 years old at the time of signing the Informed Consent Form (ICF).\n* Diagnosed as SLE\u002FImmune-Mediated Necrotizing Myopathy (IMNM)\u002FNeuromyelitis Optica Spectrum Disorders (NMOSD)\u002FMultiple Sclerosis (MS)\u002FMyasthenia Gravis (MG)\u002FSystemic Sclerosis (SSc) according to recognized diagnostic criteria for at least 6 months.\n* Remains disease active or relapses after treatment with standard of care therapy for at least 8 weeks with the dose stable for more than 2 weeks; patients should have been treated with at least two immunosuppressants (including immunosuppressants, biologics, and disease-modifying drug (DMD) ).\n* Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.\n\nExclusion Criteria:\n\n* Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.\n* Uncontrolled active infection.\n* Live vaccine injection within 4 weeks prior to signing the ICF.\n* Major organ transplantation history or bone marrow\u002Fhematopoietic stem cell transplantation history.\n* Severe cardiovascular diseases within the past 6 months prior to screening.\n* ≥ Grade 2 bleeding within the past 30 days prior to screening, or requiring long-term anticoagulants treatment.\n* Inadequate washing time for previous treatment.\n* Previously treated with CAR-T cell products or genetically modified T cell therapies.\n* Pregnant or lactating women.\n* Severe central nervous system diseases or pathological changes.\n* Malignancy history within 5 years prior to signing the ICF.",{"count":471,"type":22},30,[25],"This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy",[475,476,353,29,477,478],"Systemic Lupus Erythematosus (SLE)","Immune-mediated Necrotizing Myopathy (IMNM)","Myasthenia Gravis","Systemic Sclerosis (SSc)",[73],"2025-07-21",{"date":482,"type":45},"2025-07-25",{"date":484,"type":45},"2024-03-20",{"date":486,"type":22},"2040-03",{"name":488,"class":52},"RenJi Hospital",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":450,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":514},"100469654","phase-1-safety-pk-and-biodistribution-of-18f-op-801-in-patients-with-als-ad-ms-pd-and-healthy-volunteers-100469654","NCT05395624","Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers","A Phase 1\u002F2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers","Inclusion Criteria:\n\n1. Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to the conduct of any study related procedures.\n2. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and\u002For bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the local laboratory's defined ranges.\n3. Female subjects of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male subjects must agree to practice abstinence from sexual intercourse or use a medically accepted contraceptive regimen (including hormonal contraceptives) during their participation in the study and for 90 days (males) or 6 months (females) after Day 1. Medically accepted contraceptive methods are defined as those with 90% or greater efficacy and are as follows:\n\n   1. Male subjects: condoms or surgical sterilization of subject at least 26 weeks before the Screening Visit (i.e., vasectomy).\n   2. Female subjects:\n\n      1. Surgical sterilization at least 26 weeks before the Screening Visit (includes hysterectomy or bilateral tubal ligation, bilateral oophorectomy, or salpingectomy);\n      2. Intrauterine device or diaphragm with spermicide for at least 12 weeks before the Screening Visit; or\n      3. Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks before the Screening Visit.\n4. If male, subjects must agree to abstain from sperm donation through 90 days after the Day 1 Visit.\n5. Female subjects may not be pregnant, lactating, or breastfeeding.\n6. Female subjects of childbearing potential must have negative result for pregnancy test at Screening and Check-in.\n7. Subjects must have an estimated glomerular filtration rate (eGFR) of \\>45 mL\u002Fmin\u002F1.73m2 at Screening.\n8. C-reactive protein level ≤10 mg\u002FdL.\n9. Subjects must be willing and able to abide by all study requirements and restrictions.\n\n   Inclusion Criteria Specific to ALS Subjects:\n10. Adult (Age 18 to 80, inclusive) at the Screening Visit\n11. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the modified El Escorial criteria.\n12. Forced vital capacity (FVC) of ≥50%; or if in the opinion of the investigator can lay flat for up to 90 minutes. If FVC has been performed within the past 6 months, this data may be used at the discretion of the investigator.\n13. For ALS subjects, medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor.\n\n    Inclusion Criteria Specific to AD Subjects\n14. Adult (Age 40 to 80, inclusive) at the Screening Visit\n15. Clinical diagnosis of early stage dementia, Alzheimer type, plus positive Aβ and tau PET imaging, cerebrospinal fluid (CSF) and\u002For plasma biomarkers consistent with 2018 NIA-AA criteria\n16. MMSE score \\>20 at Screening\n17. AD medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor.\n\n    Inclusion Criteria Specific to MS Subjects:\n18. Adult (Age 18 to 70, inclusive) at the Screening Visit\n19. MS medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor.\n\n    Inclusion criteria specific to subjects with RRMS:\n20. Diagnosis of RRMS based on 2017 McDonald criteria\n21. If not newly diagnosed, subjects should have at least 1 documented relapse in the last 24 months.\n22. \"Active disease\" subjects should have at least 1 Gadolinium-enhancing (Gd+) T1-weighted brain or spinal cord lesion at Screening MRI.\n23. \"Disease in remission\" subjects should have no Gd+ T1-weighted brain or spinal cord lesions at Screening MRI and stable clinical symptoms for at least 3 months prior to Day 1.\n24. EDSS score between 2.0 and 5.5 inclusive at Screening\n\n    Inclusion criteria specific to subjects with progressive MS:\n25. Diagnosis of PPMS or SPMS based on 2017 McDonald criteria\n26. EDSS score between 3.0 and 6.5 inclusive at Screening\n27. No evidence of relapse in the prior 6 months\n28. Neurological exam and symptom stability for ≥30 days prior to Day 1\n29. Documented evidence of disability progression in the past 24 months not temporally related to a relapse\n\n    Inclusion Criteria Specific to PD Subjects:\n30. Adult (Age 55 to 80, inclusive) at the Screening Visit\n31. Diagnosis of definite, idiopathic Parkinson's disease according to UK Parkinson's Society Brain Bank diagnostic criteria\n32. PD medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor.\n\nOverall Exclusion Criteria - For All Subjects:\n\nSubjects meeting any of the following criteria will be excluded from this study:\n\n1. Body weight \\>120 kg\n2. Evidence of clinically significant or past medical history of hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies) or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism or excretion of study drug or place the subject at an unacceptable risk as a participant in this study\n3. History of recurrent kidney or liver malignancy\n4. Pacemaker or defibrillator or any non-removable metallic foreign objects in the body not compatible with MRI\n5. Inability to lie in a PET\u002FCT or PET\u002FMRI scanner for up to 90 minutes at a time\n6. Laboratory results (serum chemistry, hematology, coagulation and urinalysis) outside the normal range at Screening and Check-In and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) more than 3 times above the upper limit of normal at screening and\u002For check-in is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator and with approval from the Medical Monitor.\n7. Resolved acute illness considered clinically significant by the Investigator within 10 days prior to Screening\n8. History of alcoholism or drug abuse within 2 years prior to Screening. No cannabinoid drug use for at least 10 days prior to Day 1.\n9. Positive urine drug test, marijuana test or cotinine test at Screening or Check-In\n10. Any immunizations within the 28 days prior to screening\n11. Received any other investigational medicinal product within 30 days or 5 half-lives (whichever is longer) prior to Day 1\n12. Corticosteroid treatment (e.g., prednisone, solumedrol) within 30 days of Baseline\n13. Treatment with any of the following classes of nonsteroidal anti-inflammatory drugs (NSAIDS): carboxylic acids, enolic acids, cyclooxygenase (COX) II inhibitors within 14 days of Day 1\n14. Lost or donated \\>450 mL of whole blood or blood products within 30 days prior to Screening\n15. MRI exclusion criteria: findings that may interfere with interpretation of the PET imaging, including but not limited to significant cortical\u002Fsubcortical cerebrovascular disease, infectious disease, space-occupying lesions, hydrocephalus or other abnormalities associated with CNS disease not related to ALS, AD, MS or PD\n16. CT exclusion criteria include any medical device or metallic implant that may interfere with image acquisition or affect image reconstruction (e.g., CT attenuation correction).\n17. Investigator has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements\n18. Has any finding that, in the view of the Investigator and Medical Monitor, would compromise the subject's safety in the trial\n\n    Exclusion Criteria Specific to MS Subjects:\n19. Clinical signs or laboratory findings suggestive of neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-associated encephalomyelitis (i.e., presence of anti-NMO \\[aquaporin-4\\] antibodies or anti-MOG antibodies)\n20. Diagnosis of progressive multifocal leukoencephalopathy (PML)\n\n    Exclusion Criteria Specific to PD Subjects:\n21. Secondary, atypical, or genetic parkinsonism\n\n    Exclusion Criteria Specific to HV Subjects:\n22. Clinically relevant finding on physical examination at Screening\n23. Family history of neurological disease that may confound interpretation of imaging results\n24. History of any central nervous system disorder or brain trauma that could cause imaging abnormalities in the opinion of the Principal Investigator and Medical Monitor",{"count":497,"type":22},65,[25,26],"This is a Phase 1\u002F2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.",[501,502,503,29],"Amyotrophic Lateral Sclerosis (ALS)","Parkinson Disease (PD)","Alzheimer Disease (AD)","2025-04-30",{"date":506,"type":45},"2025-05-02",{"date":508,"type":45},"2023-02-02",{"date":510,"type":22},"2026-05-01",{"name":512,"class":513},"Ashvattha Therapeutics, Inc.","INDUSTRY",3,{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":450,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":523,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":525,"conditions":526,"keywords":530,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":53},"100452900","imaging-the-interplay-between-axonal-damage-and-repair-in-multiple-sclerosis-100452900","NCT05177523","Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER: Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER","Inclusion Criteria for patients:\n\n* Patients may be diagnosed with:\n\n  1. active RRMS (n=100): Relapsing-remitting course and \\> 1 clinical relapse and\u002For signs of MRI activity (\\> 1 Gd enhancing lesion) during the last year before study enrollment.\n  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and\u002For signs of MRI activity during the last year before study enrollment.\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nInclusion criteria for healthy controls:\n\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nExclusion Criteria for patients and healthy controls:\n\n* Pregnancy\n* Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).\n* Inability to give consent",{"count":524,"type":22},300,"This project is to:\n\n1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.\n2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.\n3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.",[29,527,528,529],"Relapsing-remitting Multiple Sclerosis (RRMS)","Secondary-progressive Multiple Sclerosis (SPMS)","Primary Progressive Multiple Sclerosis (PPMS)",[531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546],"axonal damage","axonal demyelination","axonal degeneration","axonal loss","axonal disorganization","axonal repair","axonal remyelination","axonal reorganization","Advanced MRI (aMRI)","Neurite Orientation Dispersion and Density Imaging (NODDI)","Diffusion Kurtosis (DK)","Magnetization Transfer Imaging (MTI)","Multi-echo Susceptibility-Based imaging (SBI)","Myelin Water Imaging (MWI)","T1 relaxometry (quantitative T1, qT1)","machine learning technique","2024-12-13",{"date":549,"type":45},"2024-12-16",{"date":551,"type":45},"2018-09-04",{"date":553,"type":22},"2028-12",{"name":319,"class":52},{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":17,"minAge":562,"maxAge":563,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":4},"100570632","pilot-of-the-virtual-memory-attention-and-problem-solving-skills-intervention-for-persons-with-multiple-sclerosis-ms-100570632","NCT06709768","Pilot of the Virtual Memory Attention and Problem Solving Skills Intervention for Persons With Multiple Sclerosis (MS)","Virtual Memory Attention and Problem Solving Skills for Persons With MS (MAPSS-MS) Pilot","Inclusion Criteria: Age 21 -85 years old, reside in the United States, MS diagnosis for at least 1 years, access and ability to use phone, computer and Internet, Score of ≥10 on the Perceived Deficits Questionnaire (PDQ), adequate vision and motor skills to use the computer for testing and to participate in the intervention.\n\nExclusion Criteria:A diagnosis of dementia\u002Fhead injury, inability to speak English, severe functional limitation that makes use of computer for intervention and testing impossible; prior participation in a cognitive rehab intervention during the last year; currently using Brain HQ at home.\n\n\\-","21 Years","85 Years",{"count":565,"type":22},34,[94],"The goal of this pilot clinical trial is to study is to test the feasibility and effects of a virtual (remote) version of a cognitive rehabilitation intervention - Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS). We have already tested this intervention \"in person\" and found it to be effective at helping persons with MS improve their cognitive function learn. We are now testing the MAPSS-MS intervention using a virtual or remote format. The main questions this pilot study aims to answer are:\n\n1. What is the feasibility of the Virtual MAPSS-MS intervention\n2. Compared with persons in the wait list control group, will persons receiving the Virtual MAPSS-MS intervention have better overall neurocognitive function and 3. ) Compared with persons in the wait list control group, will persons receiving the Virtual MAPSS-MS intervention have improved stress, self-efficacy for cognitive everyday tasks, use of compensatory strategies and improved depressive symptoms, fatigue, sleep and pain.\n\nParticipants will be asked to take part in the MAPSS-MS intervention virtually and complete surveys and cognitive tests online at three time points: before the eight-week intervention, immediately after the intervention and six-weeks after the intervention.\n\nThe virtual MAPSS-MS has two components (a) Group sessions via zoom with an expert leader and (b) a computer assisted brain games (Brain HQ) program. The eight online group sessions (2 hours once per week) will address common cognitive concerns experienced by persons with MS and strategies that may be helpful. Participants will also be provided access to Brain HQ, a computerized training program, and asked to practice these games for 20-30 minutes on 5 or 6 days per week.",[29],[570],"cognitive rehabilitation","2024-11-25",{"date":573,"type":45},"2024-11-29",{"date":575,"type":22},"2024-12",{"date":577,"type":22},"2025-11",{"name":579,"class":52},"University of Texas at Austin",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":587,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":589,"conditions":590,"keywords":596,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":53},"100557708","sun-yat-sen-cohort-of-cns-idiopathic-inflammatory-demyelinating-diseases-100557708","NCT06541626","Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","Sun Yat-Sen Prospective Cohort Study of Central Nervous System Idiopathic Inflammatory Demyelinating Diseases","Inclusion Criteria:\n\n1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD);\n2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E);\n3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of tumors or diagnosis of central nervous system tumors;\n2. Infectious lesions of the central nervous system;\n3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain\u002Fspinal cord;\n4. Non-compliance with treatment and follow-up.",{"count":588,"type":22},450,"The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions.\n\nThe main questions it aims to answer are:\n\nQuestion 1: Clarify the clinical characteristics and prognostic factors of various diseases (MS, NMOSD, MOGAD, etc.) within IIDD in the Chinese population.\n\nQuestion 2: Analyze the relationship between biomarkers and the occurrence, progression, and prognosis of CNS IIDD cases in our hospital.\n\nParticipants will\n\n1. Receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions.\n2. Receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.",[237,591,592,593,594,595],"Neuromyelitis Optica Spectrum Disorders","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Acute Disseminated Encephalomyelitis","Clinically Isolated Syndrome","Demyelinating Disorder",[597,598],"CNS IIDD","follow-up","2024-08-02",{"date":601,"type":45},"2024-08-07",{"date":603,"type":45},"2024-01-01",{"date":605,"type":22},"2035-12-31",{"name":607,"class":52},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":609,"slug":610,"hasResults":11,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":450,"sex":614,"minAge":18,"maxAge":144,"enrollmentInfo":615,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":617,"conditions":618,"keywords":620,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":53},"100440100","pregnancy-cohort-in-multiple-sclerosis-ms-100440100","NCT05010902","Pregnancy Cohort in Multiple Sclerosis (MS)","Inclusion Criteria:\n\n* age \\> 18 years\n* signed informed consent\n* diagnosis of multiple sclerosis or clinically isolated syndrome\n\nExclusion Criteria:\n\n* clinically relevant comorbidities\n* contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium\n* alcohol or drug abuse","FEMALE",{"count":616,"type":22},100,"Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life. In this prospective observational study, we obtain data on the outcome of pregnancies in MS patients and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.",[29,619],"Clinically Isolated Syndrome (CIS)",[621],"Pregnancy","2024-07-03",{"date":624,"type":45},"2024-07-05",{"date":626,"type":45},"2013-01-01",{"date":628,"type":22},"2026-12-31",{"name":630,"class":52},"Charite University, Berlin, Germany",{"id":632,"slug":633,"hasResults":11,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":450,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":23,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":53},"100536885","increasing-physical-activity-for-adults-with-multiple-sclerosis-ms-100536885","NCT06270641","Increasing Physical Activity for Adults With Multiple Sclerosis (MS)","Increasing Physical Activity Via Provider Prescription and Engagement: Efficacy of ExerciseRx for Adults With Multiple Sclerosis (MS)","Inclusion Criteria:\n\n* Provider-confirmed diagnosis of MS using revised 2017 McDonald criteria\n* \\> 18+ years of age\n* Patient determined disease steps (PDDS) score \\\u003C 3, indicating the potential for some gait disability although typically ambulates without an assistive device\n* Insufficiently active, defined as \\\u003C 150 minutes of physical activity per week, assessed using the PAVS in the EHR in clinics as part of the routine patient intake process\n* Use of an iPhone with software version iOS13+ or an Android phone 4.1+\n* Agree to install and use the ExerciseRx app for the entire study period and keep their phone on them during the daytime (e.g., pocket, bags, hands)\n\nExclusion Criteria:\n\n* Recent (past 4 weeks) or planned surgery during the study period which may impact engaging in step counts\n* MS relapse within the last 30 days\n* Plans to travel internationally during the study period, which could interfere with server uploads of mobile phone data\n* Those at a higher risk of falling or injury from falls or unable to safely exercise due to other medical conditions (e.g. heart conditions, diabetes or conditions made worse by walking or physical activity)",{"count":639,"type":22},106,[94],"This study aims to advance the scientific understanding and potential future implementation of physical activity promotion by testing the efficacy of a phone-based app for increasing activity in insufficiently active patients with multiple sclerosis (MS).",[29,643,644],"Fatigue","Physical Inactivity","2024-02-21",{"date":647,"type":45},"2024-02-22",{"date":649,"type":22},"2024-02-16",{"date":651,"type":22},"2026-09-30",{"name":136,"class":52}]